Current role
Christopher Gibson
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Christopher Gibson
Recursion Pharmaceuticals, Inc. reported in an 8-K filed November 20, 2024 that Christopher Gibson was appointed President of the Company, effective November 20, 2024. The proxy statement of Recursion Pharmaceuticals, Inc. reports total compensation of $9,607,508 for Christopher Gibson in fiscal 2025, including a base salary of $680,000. Disclosed compensation is on record for 6 fiscal years.
“On November 19, 2024, the Board appointed Christopher Gibson, Ph.D. ("Dr. Gibson"), age 41, current Chief Executive Officer of the Company and a member of the Board, to serve also as President of the Company, effective as of November 20, 2024.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2024-11-20–present
-
2013-01-01–2025-04-28
Last confirmed by a filing; no departure on record
-
Start not stated–2025-04-28
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Recursion Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- Christopher C. Gibson CEO, Board Member
- Najat Khan CEO
- Najat Khan, Ph.D. CEO, Board Member
- Christopher Gibson, Ph.D. Chairman
- Robert Hershberg, M.D., Ph.D. Chairman
- Ben Taylor CFO
- Kristen Rushton COO
- Tina Marriott COO
- David Hallett CTO, Board Member
- Blake Borgeson Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Recursion Pharmaceuticals, Inc. (RXRX) | former Chief Executive Officer and President and current Chair of the Board | $680,000 | $9,607,508 |
| 2024 | Recursion Pharmaceuticals, Inc. (RXRX) | Chief Executive Officer | $600,000 | $8,499,587 |
| 2023 | Recursion Pharmaceuticals, Inc. (RXRX) | Chief Executive Officer | $560,833 | $8,613,209 |
| 2022 | Recursion Pharmaceuticals, Inc. (RXRX) | Chief Executive Officer | $497,500 | $6,315,903 |
| 2021 | Recursion Pharmaceuticals, Inc. (RXRX) | Chief Executive Officer | $485,417 | $673,591 |
| 2020 | Recursion Pharmaceuticals, Inc. (RXRX) | Chief Executive Officer | $269,643 | $2,584,448 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.